A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Eli Lilly and Company
Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Have no significant body weight change for the 3 months prior to screening Part A and Part E: * Are considered healthy * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening Part B: * Have a BMI of 27 to 45 kg/m2 at screening Part C: * Have a BMI of 25 to 45 kg/m2 at screening Part D: * Have type 2 diabetes * Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening * Have a BMI of 27 to 45 kg/m2 at screening Exclusion Criteria: * Have had an acute cardiovascular condition within the past 6 months prior to screening * Have li…
Interventions
- DrugLY4086940
Administered orally
- DrugPlacebo
Administered orally
- DrugLY4086940
Administered IV
Locations (6)
- Fortrea Clinical Research UnitDaytona Beach, Florida
- Clinical Pharmacology of MiamiMiami, Florida
- CenExel iResearch, LLCDecatur, Georgia
- Fortrea Clinical Research UnitDallas, Texas
- Endeavor Clinical TrialsSan Antonio, Texas
- Lilly Centre for Clinical PharmacologySingapore